A federal advisory panel concluded today that a local pharmaceutical company's new weight-loss drug posed too many risks and not enough benefits, recommending that the drug not be approved by the FDA.
The drug, developed by Mountain View's Vivus Inc., is called Qnexa, and combines two compounds -- phentermine and topiramate -- to battle weight gain by controlling appetite and satiety.
According to the Wall Street Journal, voted 6-to-10 against a question asking whether the "overall risk-benefit assessment of Qnexa is favorable to support approval."
Dan Budwick, a spokesman for Qnexa, said the ruling is only a recommendation and that a final FDA decision will not come until Oct. 28.
If the drug is ultimately approved, it will be the first weight-loss drug to hit the market in more than a decade.
Despite promising results in reducing weight loss during clinical trials, the panel was concerned about the potential for long term side-effects, such as heart problems and birth defects. Many members of the panel said they would not feel comfortable approving the drug until they saw more data, according to the Journal's report.